DOI: 10.5061/dryad.zs7h44jkg
title: Data from: Cost effectiveness analysis of hormone therapy for breast cancer in Japan

description: Breast cancer is one of the deadliest diseases in the world. It accounts
 for 22.2 % of all cancers and is the most common site of cancer in women
 in Japan. Although hormone therapy with aromatase inhibitors or tamoxifen
 has been widely used, it is unclear which agent is more cost-effective.
 This study examined the cost-effectiveness of anastrozole as an aromatase
 inhibitor from a healthcare payer's perspective compared to tamoxifen
 in Japan. A Markov model, for comparison, of anastrozole with tamoxifen as
 a reference agent, was developed using data from a randomized clinical
 trial conducted in Japan. The costs were derived from the Japanese Health
 Care Fee Index for 2022. Based on the results of a questionnaire on the
 general health-related quality of life associated with cancer (FACT-G),
 utilities were converted to EuroQol-5 Dimension-5 Level. The time horizon
 was set to 10 years. In addition, deterministic and probabilistic
 sensitivity analyses were conducted. Anastrozole was dominated by
 tamoxifen. One-way sensitivity analysis showed the expected value (EV) of
 incremental net monetary benefit for anastrozole was the most sensitive to
 the pharmaceutical "drug price of anastrozole in FY2022," where
 the generic drug price was applied. The EV remained negative across the
 other parameters. Probabilistic sensitivity analysis revealed that
 anastrozole dominance over tamoxifen was 47.2 %. Anastrozole was less
 cost-effective than tamoxifen in Japan. Our findings support clinical
 practice and suggest payers and policymakers promote cost-effective
 therapies.
description: # Data from: Cost effectiveness analysis of hormone therapy for breast
 cancer in Japan
 [https://doi.org/10.5061/dryad.zs7h44jkg](https://doi.org/10.5061/dryad.zs7h44jkg) ## Description of the data and file structure #### Author(s) Naoto Nakagawa, Phar.D., Ph.D. School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan 31-1 Misumido, Tomita-machi, Koriyama, Fukushima 963-8611, Japan Email: [n-nakagawa@pha.ohu-u.ac.jp](mailto:n-nakagawa@pha.ohu-u.ac.jp) Yuta Chiba School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan 31-1 Misumido, Tomita-machi, Koriyama, Fukushima 963-8611, Japan Email: [723404@ohu-u.jp](mailto:723404@ohu-u.jp) Leanne Lai College of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan Email: [LL33317@gmail.com](mailto:LL33317@gmail.com) ## File list CEA_input_data.xlsx PSA_input_data.xlsx ### File descriptions #### Details for: CEA_input_data.xlsx The file is a table to analyze for input with TreeAge Pro. Format(s): .csv Dimensions: 15 rows x 5 columns Variables: * Name: c_XXX means cost variables (unit is 'yen'), p_XXX means probability variables, and u_XXX means utility variables (unit is 'QALY'). * Description: definition of each variable. * Root Definition: individual variables for a base-case scenario. * Low and High columns: the low and the high numbers for one-way sensitivity analysis. ANA: anastrozole, TAM: tamoxifen, FY: fiscal year. #### Details for: PSA_input_data.xlsx This file is a table to analyze the input for probabilistic sensitivity analysis with TreeAge Pro. Format(s): .csv Dimensions: 13 rows x 5 columns Variables: * Type_Distribution: data distribution. Beta shows that a value is from 0 to 1.  * Name: d_XXX means distribution variables. * Description: Description of each distribution variables. * Param 1: alpha for beta distribution parameter * Param 2: beta for beta distribution parameter and lambda for gamma distribution parameter ANA: anastrozole, TAM: tamoxifen, FY: fiscal year.